| I doubt the rights to 132 in outer mongolia would bring in much, but what about Europe? Japan? Might that bring in 50 million apiece, or more? And since Epratuzumab is continuing to be tested in a variety of liquid malignancies, including an Yttrium-90 labeled version, how can you attribute no value to it; you think there is NO company out there that would be willing to buy Emab, in all it's versions, lock stock and barrel? Vmab clearly has some activity in ITP, you don't think a big pharma could take a chance on that and get it across the line? You don't think the licensing of 130 would bring in any money? The fact is, during the CC, Venbio made no assurances about anything, be that selling shares, or selling rights to the pipeline. They were quite clear that they would need to go in, evaluate what they had, and make decisions. You seem to be attributing plans to venbio that to me, they clearly do not have. As to your final question, I think Lonnie answered just about as I would. The current board needs to go, and the reign of the King Goldenberg and Queen Cindy needs to be over. This company needs to be run like a company, not a fiefdom. |
